LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS)
("Compass"), a biotechnology company dedicated to accelerating patient access to
evidence-based innovation in mental health, and Mindful Health Solutions (MHS),
one of the US's leading providers of innovative behavioral health care, today
announced that they have entered into a research collaboration agreement to
inform the development of a scalable and cost-effective delivery model for
COMP360 psilocybin treatment, if approved for treatment-resistant depression
(TRD). This is the latest of several collaborations for Compass, intended to
better understand a range of potential approaches to deliver COMP360 to patients
in different care settings.
MHS offers comprehensive mental health care services for patients living with
TRD and other mental health conditions. They focus on early adoption of
advanced, interventional treatment options, as part of a long-term, holistic
care model that includes medication management and psychotherapy. MHS operates
over 20 outpatient clinics located across California, Washington, Texas, and
Georgia.
"It is crucial that we understand how different mental health service providers
are positioned to deliver COMP360 psilocybin treatment to patients, should it
receive FDA approval," said Kabir Nath, CEO of Compass Pathways. "By joining
forces with MHS, Compass will have the opportunity to learn from a leading
provider of innovative behavioral health care for people living with treatment-
resistant depression and other difficult-to-treat mental health conditions."
The collaboration with MHS will include an in-depth information exchange on
Compass's potential delivery model for investigational COMP360 psilocybin
treatment, and how it might fit into a healthcare delivery system similar to
MHS. Compass and MHS will chart the depression and TRD patient pathway and
investigate challenges with the current patient care experience, including
potential approaches to address these. MHS will complete training and learning
sessions on Compass's psychological support model and therapist training program
and conduct research to better understand therapist training needs. Compass and
MHS will exchange information on model treatment rooms, site activation
services, and coding and reimbursement considerations related to psychedelic
treatments.
"There are millions of people in the US living with depression for whom existing
treatments do not work," said John Minahan, CEO of Mindful Health Solutions.
"Part of MHS's mission is to make innovative treatments accessible to everyone
who may benefit from them. As such, we are proud to collaborate with Compass
Pathways and to contribute to learning how COMP360 psilocybin treatment may be
most effectively delivered to patients, if approved for TRD."
Compass has previously announced research collaboration agreements with
Greenbrook TMS, a leading provider of interventional psychiatric treatments such
as transcranial magnetic stimulation; Hackensack Meridian Health, a leading not-
for-profit health care organization and the largest, most comprehensive and
truly integrated network in New Jersey, addressing the full continuum of care
for people living with TRD; and Journey Clinical, a leading psychedelic-assisted
psychotherapy platform with the largest network of licensed therapists focused
on psychedelics in the US.
About Compass Pathways?
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to
accelerating patient access to evidence-based innovation in mental health. Our
focus is on improving the lives of those who are living with mental health
challenges and who are not helped by current treatments. We are pioneering the
development of a new model of psilocybin treatment, in which our proprietary
formulation of synthetic psilocybin, COMP360, is administered in conjunction
with psychological support. COMP360 has been designated a Breakthrough Therapy
by the U.S. Food and Drug Administration (FDA) and has received Innovative
Licensing and Access Pathway (ILAP) designation in the UK for treatment-
resistant depression (TRD).
We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in
TRD, the largest randomized, controlled, double-blind psilocybin treatment
clinical program ever conducted. Previously, we completed a phase 2b study with
top line data showing a statistically significant (pÂ